EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Activated sputum eosinophils associated with exacerbations in children on mepolizumab

Gabriella E Wilson, James Knight, Qing Liu, Ashish Shelar, Emma Stewart, Xiaomei Wang, Xiting Yan, Joshua Sanders, Cynthia Visness, Michelle Gill, Rebecca Gruchalla, Andrew H Liu und 9 weitere

Journal of Allergy and Clinical Immunology · 2024-08 · 154 (2) · 297-307.e13

DOI: 10.1016/j.jaci.2024.01.031 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Allergy and Clinical Immunology, 2024-08. Verfasst von Gabriella E Wilson und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Yale School of Medicine, New Haven, Conn. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Eosinophils, Sputum, Asthma. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, NCATS NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: MUPPITS-2 was a randomized, placebo-controlled clinical trial that demonstrated mepolizumab (anti-IL-5) reduced exacerbations and blood and airway eosinophils in urban children with severe eosinophilic asthma. Despite this reduction in eosinophilia, exacerbation risk persisted in certain patients treated with mepolizumab. This raises the possibility that subpopulations of airway eosinophils exist that contribute to breakthrough exacerbations. OBJECTIVE: We aimed to determine the effect of mepolizumab on airway eosinophils in childhood asthma. METHODS: Sputum samples were obtained from 53 MUPPITS-2 participants. Airway eosinophils were characterized using mass cytometry and grouped into subpopulations using unsupervised clustering analyses of 38 surface and intracellular markers. Differences in frequency and immunophenotype of sputum eosinophil subpopulations were assessed based on treatment arm and frequency of exacerbations. RESULTS: Median sputum eosinophils were significantly lower among participants treated with mepolizumab compared with placebo (58% lower, 0.35% difference [95% CI 0.01, 0.74], P = .04). Clustering analysis identified 3 subpopulations of sputum eosinophils with varied expression of CD62L. CD62Lint and CD62Lhi eosinophils exhibited significantly elevated activation marker and eosinophil peroxidase expression, respectively. In mepolizumab-treated participants, CD62Lint and CD62Lhi eosinophils were more abundant in participants who experienced exacerbations than in those who did not (100% higher for CD62Lint, 0.04% difference [95% CI 0.0, 0.13], P = .04; 93% higher for CD62Lhi, 0.21% difference [95% CI 0.0, 0.77], P = .04). CONCLUSIONS: Children with eosinophilic asthma treated with mepolizumab had significantly lower sputum eosinophils. However, CD62Lint and CD62Lhi eosinophils were significantly elevated in children on mepolizumab who had exacerbations, suggesting that eosinophil subpopulations exist that contribute to exacerbations despite anti-IL-5 treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedEosinophilsSputumAsthmaAnti-Asthmatic AgentsHumansChildMaleFemaleAdolescentInterleukin-5Disease Progression

Stichwörter der Autor:innen

Interleukin-5asthmamass cytometrysputum

Substanzen

mepolizumabAntibodies, Monoclonal, HumanizedAnti-Asthmatic AgentsInterleukin-5

Autor:innen und Institutionen

  • Department of Internal Medicine, Yale School of Medicine, New Haven, Conn.
  • Department of Genetics and Yale Center for Genome Analysis, Yale School of Medicine, New Haven, Conn.
  • Committee on Immunology, University of Chicago, Chicago, Ill.
  • Rho Federal Systems Division, Inc, Durham, NC.
  • Department of Pediatric Infectious Diseases, Washington University in St Louis School of Medicine, St Louis, Mo.
  • Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Tex.

Förderung

  • NIAID NIH HHS
  • NCATS NIH HHS
  • NHLBI NIH HHS
  • NLM NIH HHS
  • GlaxoSmithKline Inc
  • National Institutes of Health
  • GlaxoSmithKline
  • National Institute of Allergy and Infectious Diseases

Zitieren

APA

Wilson, G. E., Knight, J., Liu, Q., Shelar, A., Stewart, E., Wang, X., Yan, X., Sanders, J., Visness, C., Gill, M., Gruchalla, R., Liu, A. H., Kattan, M., Khurana Hershey, G. K., Togias, A., Becker, P. M., Altman, M. C., Busse, W. W., Jackson, D. J., …, & Chupp, G. L. (2024). Activated sputum eosinophils associated with exacerbations in children on mepolizumab. Journal of Allergy and Clinical Immunology, 154(2), 297-307.e13. https://doi.org/10.1016/j.jaci.2024.01.031

Vancouver

Wilson GE, Knight J, Liu Q, Shelar A, Stewart E, Wang X, et al. Activated sputum eosinophils associated with exacerbations in children on mepolizumab. Journal of Allergy and Clinical Immunology. 2024;154(2):297-307.e13. doi:10.1016/j.jaci.2024.01.031

BibTeX
@article{Wilson2024,
  author = {Wilson, Gabriella E and Knight, James and Liu, Qing and Shelar, Ashish and Stewart, Emma and Wang, Xiaomei and Yan, Xiting and Sanders, Joshua and Visness, Cynthia and Gill, Michelle and Gruchalla, Rebecca and Liu, Andrew H and Kattan, Meyer and Khurana Hershey, Gurjit K and Togias, Alkis and Becker, Patrice M and Altman, Matthew C and Busse, William W and Jackson, Daniel J and Montgomery, Ruth R and Chupp, Geoffrey L},
  title = {Activated sputum eosinophils associated with exacerbations in children on mepolizumab},
  journal = {Journal of Allergy and Clinical Immunology},
  year = {2024},
  volume = {154},
  number = {2},
  pages = {297--307.e13},
  doi = {10.1016/j.jaci.2024.01.031}
}
Kostenlos starten →